- Q1 2024 Verrica Pharmaceuticals Inc Earnings Call TranscriptMay 13, 2024€7.31 (+1.81%)Earnings
- Q4 2023 Verrica Pharmaceuticals Inc Earnings Call TranscriptFeb 29, 2024€5.15 (-0.96%)Earnings
- Q3 2023 Verrica Pharmaceuticals Inc Earnings Call TranscriptNov 09, 2023€3.04 (-10.59%)Earnings
- Verrica Pharmaceuticals Inc to Host KOL Event (Virtual) TranscriptOct 11, 2023
- Verrica Pharmaceuticals Inc to Discuss FDA Approval of YCANTH Call TranscriptJul 24, 2023
- Verrica Pharmaceuticals Inc at Jefferies Healthcare Conference TranscriptJun 08, 2023
- Verrica Pharmaceuticals Inc at RBC Capital Markets Global Healthcare Conference TranscriptMay 17, 2023
- Verrica Pharmaceuticals Inc at Needham Healthcare Conference (Virtual) TranscriptApr 17, 2023
- Verrica Pharmaceuticals Inc at Cowen Health Care Conference TranscriptMar 06, 2023
- Verrica Pharmaceuticals Inc at H C Wainwright Global Investment Conference (Virtual) TranscriptSep 14, 2022
- Verrica Pharmaceuticals Inc at RBC Capital Markets Global Healthcare Conference (Virtual) TranscriptMay 19, 2021
- Verrica Pharmaceuticals Inc VIRTUAL PANEL: The Pursuit of Molluscum - Beetlejuice and Nobel Prizes TranscriptSep 22, 2020
Verrica Pharmaceuticals Inc at Jefferies Healthcare Conference Transcript
Okay, good afternoon, everybody. Thank you for joining us. And thank you for enduring the smoke and being here. For those of you who don't know me, I'm Glen Santangelo. I cover the specialty pharmaceutical sector at Jefferies in addition to healthcare information technology.
For our next presentation, we're happy to have Verrica with us here today. Representing the company on my left is the President and CEO of the company, Ted White. To his left is Joseph Bonaccorso, who is the Chief Commercial Officer of the company. And in the audience here somewhere, Terry Kohler, who is the CFO of the company. So with that, why don't we get started?
(Conference Instructions) All right. So, Ted, welcome. Why not maybe to get started, help us level set the conversation. Give everybody a brief overview of the company, a slight description of the lead asset, VP-102. So people -- then we can jump right into the Q&A from there.
Sure. Thanks, Glen.
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)